search innovation
New drug for the treatment and prophylaxis of diseases caused by hsv-1 virus
keywords: herpes simplex, herpes simplex virus, HSV-1, drug, infections, biochemistry, biophysics, biotechnology
offer number: 407


Potential drug: PEG-PMAPTAC block copolymer

Application: prevention and treatment of diseases caused by HSV-1 virus


Herpes simplex virus type 1 (HSV-1) is considered to be one of the most frequent pathogens acquired by humans. The statistics show that 50% to 90% of individuals worldwide are seropositive for that virus. The symptoms of primary HSV-1 infections include appearance of watery blisters (cold sores) on the skin, tongue, lips, genitals or buccal mucosa and keratitis. However, HSV-1 infections can cause life-threatening diseases like neurological disorders, encephalitis, blindness and even death.

No effective HSV vaccine is available, and therefore current research is oriented towards the development of antiviral compounds limiting the primary infection and supporting further treatment. Currently, the approved anti-HSV therapies involve mainly nucleoside analogues, such as acyclovir (ACV), which interfere with viral DNA synthesis reducing virus replication and shedding. Low bioavailability of this drug led to the development of derivatives with better pharmacokinetic parameters, e.g selenoaciclovir, valacyclovir, famciclovir, and ganciclovir. Most of these drugs undergo bioconversion within the cell to ACV. An alternative for treatment of some ACV-resistant HSV infections is foscarnet, which hampers viral polymerase activity by binding to the pyrophosphate binding site. All mentioned compounds are oriented on the same molecular target, and therefore some cross resistance is observed. For these reasons, there is a need for the development of novel anti-herpes drugs with different mechanism of action. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for the treatment of HSV-1 infection.



The main advantages of the offered drug are:

  • low-toxicity of the drug in vitro and in vivo;
  • confirmed ability to inhibit HSV-1 replication;
  • the possibility to apply as a solution/gel/lipstick/cream/powder/ointment/eye drops administered topically to the skin or eye.


The offered invention is subject of a patent application. Further research and development of the invention are continued at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for entities interested in commercial application of the invention.


Logos od European Funds, Republic of Poland, Inkubator Innowacyjności 2.0, European Union

commercial utility:  
field of science: biochemistry, biology, medical biology, pharmaceutical science, biotechnology
forms of protection: patent application
technological maturity: demanding R & D
property rights: Jagiellonian University
variants of cooperation: license, spin-off company, comercial contract research, sale

information / broker of Jagiellonian University

name and surname: Klaudia Polakowska, PhD
phone number: +48 12 664 42 13, +48 519 329 129
latest information
Big Pharma Day online
Big Pharma Day online is an industry meeting on the development of drug projects, organized by CTT CITTRU, happening on March 25, 2021. The event will include expert presentations and individual meetings.
A new, effective method for obtaining common ash cuttings
Discover a new technology for obtaining cuttings of common ash developed by the interdisciplinary research team from the Jagiellonian University and the University of Agriculture in Krakow.
Development of biotization technology for commercial and ecological production of berry fruits
The scientific team from Jagiellonian University developed an inoculum that stimulates seedling growth.
Our employees
Innovation Forum KrakówKlaster Lifescience KrakówWolves SummitPACTTJagiellońskie Centrum Innowacji
Centre for Technology Transfer CITTRU
Jagiellonian University in Kraków - POLAND
ul. Bobrzyńskiego 14,
30-348 Kraków

+48 12 664 42 00
Fundusze EuropejskieMNiSWInkubator InnowacyjnościUnia Europejska